JP2018507210A5 - - Google Patents

Download PDF

Info

Publication number
JP2018507210A5
JP2018507210A5 JP2017543828A JP2017543828A JP2018507210A5 JP 2018507210 A5 JP2018507210 A5 JP 2018507210A5 JP 2017543828 A JP2017543828 A JP 2017543828A JP 2017543828 A JP2017543828 A JP 2017543828A JP 2018507210 A5 JP2018507210 A5 JP 2018507210A5
Authority
JP
Japan
Prior art keywords
deuterium
compound
group
structural formula
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017543828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018507210A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/018222 external-priority patent/WO2016133989A1/en
Publication of JP2018507210A publication Critical patent/JP2018507210A/ja
Publication of JP2018507210A5 publication Critical patent/JP2018507210A5/ja
Pending legal-status Critical Current

Links

JP2017543828A 2015-02-18 2016-02-17 小胞モノアミン輸送体2のジメトキシフェニル系阻害剤 Pending JP2018507210A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562117654P 2015-02-18 2015-02-18
US62/117,654 2015-02-18
PCT/US2016/018222 WO2016133989A1 (en) 2015-02-18 2016-02-17 Dimethoxyphenyl inhibitors of vesicular monoamine transporter 2

Publications (2)

Publication Number Publication Date
JP2018507210A JP2018507210A (ja) 2018-03-15
JP2018507210A5 true JP2018507210A5 (enExample) 2019-03-22

Family

ID=56692737

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017543828A Pending JP2018507210A (ja) 2015-02-18 2016-02-17 小胞モノアミン輸送体2のジメトキシフェニル系阻害剤

Country Status (12)

Country Link
US (1) US10722479B2 (enExample)
EP (1) EP3258926A4 (enExample)
JP (1) JP2018507210A (enExample)
AR (1) AR103728A1 (enExample)
BR (1) BR112017017673A2 (enExample)
CA (1) CA2976229A1 (enExample)
EA (1) EA201791839A1 (enExample)
IL (1) IL253901A0 (enExample)
MA (1) MA41557A (enExample)
MX (1) MX2017010567A (enExample)
TW (1) TW201630871A (enExample)
WO (1) WO2016133989A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
WO2026050236A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA852843B (en) 1984-05-15 1985-11-27 Warner Lambert Co Bevantolol preparation
JP2009538355A (ja) * 2006-05-26 2009-11-05 オースペックス・ファーマシューティカルズ・インコーポレイテッド ジューテリウム化アミノグリシジル化合物
CA2701638A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals Inc. Pharmaceutical calcimimetics
US20100009950A1 (en) * 2008-06-30 2010-01-14 Auspex Pharmaceuticals, Inc. Substituted ethanolamines
CA2972242A1 (en) * 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20100143287A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Trifluoromethylphenyl modulators of calcium-sensing receptor
EP3351247A1 (en) * 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
PL3010543T3 (pl) * 2013-06-19 2026-01-19 Som Innovation Biotech, S.A. Środki terapeutyczne stosowane w profilaktyce i/lub leczeniu hiperkinetycznych zaburzeń ruchowych

Similar Documents

Publication Publication Date Title
JP2012503010A5 (enExample)
JP2012524085A5 (enExample)
JP2010507585A5 (enExample)
JP2009539863A5 (enExample)
JP2009538359A5 (enExample)
JP2016529228A5 (enExample)
ES2633658T3 (es) Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria
JP2009511481A5 (enExample)
TWI549692B (zh) 使心臟神經分布顯像之配位體
JP2010512343A5 (enExample)
JP5684333B2 (ja) 放射性ハロゲン標識有機化合物の製造方法
US20100076087A1 (en) Methods of reduction of interpatient variability
JP2018507210A5 (enExample)
US9526711B2 (en) Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
JP2009535405A5 (enExample)
US20100087455A1 (en) Substituted xanthine compounds
CA2768043A1 (en) Cyclopropyl modulators of p2y12 receptor
CA2631581A1 (en) Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
US20220062268A1 (en) Pharmaceutical composition for the treatment of parkinson's disease
JP2022525148A5 (enExample)
JP2025509969A5 (enExample)
CA2653209A1 (en) Deuterated aminoglycidyl compounds
US20100286124A1 (en) Prop-2-yn-1-amine inhibitors of monoamine oxidase type b
US20090247628A1 (en) Substituted phenylcyclohexylglycolates
PL219269B1 (pl) Deuterowane pochodne katecholoaminy i ich zastosowanie oraz preparaty farmaceutyczne, zawierające te związki